Luis T. Campos

2.3k total citations
29 papers, 726 citations indexed

About

Luis T. Campos is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luis T. Campos has authored 29 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luis T. Campos's work include Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Luis T. Campos is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Lung Cancer Treatments and Mutations (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Luis T. Campos collaborates with scholars based in United States, Brazil and United Kingdom. Luis T. Campos's co-authors include Beiying Ding, Vicki A. Morrison, Jennifer L. Malin, Dawn L. Hershman, Mitchell D. Wong, Peter Sportelli, Yehuda Z. Patt, John Nemunaitis, Jaffer A. Ajani and Richard Pazdur and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Surgery.

In The Last Decade

Luis T. Campos

29 papers receiving 701 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis T. Campos United States 13 441 201 145 140 114 29 726
Maki Tanioka Japan 17 335 0.8× 261 1.3× 111 0.8× 166 1.2× 89 0.8× 76 841
Merry Tetef United States 14 269 0.6× 147 0.7× 119 0.8× 118 0.8× 78 0.7× 29 581
Giovanni Codacci-Pisanelli Italy 16 564 1.3× 464 2.3× 187 1.3× 132 0.9× 122 1.1× 47 1.1k
Masafumi Takimoto Japan 13 402 0.9× 213 1.1× 171 1.2× 67 0.5× 156 1.4× 40 815
Carla Kurkjian United States 17 302 0.7× 481 2.4× 157 1.1× 130 0.9× 101 0.9× 41 830
Julian Adlard United Kingdom 11 416 0.9× 264 1.3× 127 0.9× 134 1.0× 202 1.8× 22 676
Erwan Pencreach France 17 350 0.8× 323 1.6× 200 1.4× 248 1.8× 71 0.6× 35 797
William Dahut United States 11 323 0.7× 464 2.3× 287 2.0× 190 1.4× 81 0.7× 19 887
M Chazal France 14 563 1.3× 218 1.1× 227 1.6× 89 0.6× 241 2.1× 31 837
Lei Deng China 12 330 0.7× 219 1.1× 71 0.5× 90 0.6× 70 0.6× 25 786

Countries citing papers authored by Luis T. Campos

Since Specialization
Citations

This map shows the geographic impact of Luis T. Campos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis T. Campos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis T. Campos more than expected).

Fields of papers citing papers by Luis T. Campos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis T. Campos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis T. Campos. The network helps show where Luis T. Campos may publish in the future.

Co-authorship network of co-authors of Luis T. Campos

This figure shows the co-authorship network connecting the top 25 collaborators of Luis T. Campos. A scholar is included among the top collaborators of Luis T. Campos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis T. Campos. Luis T. Campos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Campos, Luis T., et al.. (2025). Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis. Clinical & Translational Oncology. 27(7). 3100–3109. 1 indexed citations
2.
3.
Fujiki, Masato, Koji Hashimoto, Cristiano Quintini, et al.. (2022). Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy. Annals of Surgery. 276(5). 838–845. 23 indexed citations
4.
Mahalingam, Devalingam, Putao Cen, Sukeshi Patel Arora, et al.. (2019). A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. Cancers. 11(6). 833–833. 72 indexed citations
5.
Schwartzberg, Lee S., Francis P. Arena, Edward H. Kaplan, et al.. (2017). A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. Journal of Cancer. 8(10). 1872–1883. 39 indexed citations
6.
Sarantopoulos, John, Monica Mita, Michael J. Birrer, et al.. (2015). Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Targeted Oncology. 11(3). 317–327. 9 indexed citations
7.
Bendell, Johanna C., John Nemunaitis, S. Vukelja, et al.. (2011). Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 29(33). 4394–4400. 81 indexed citations
8.
Camacho, Luis H., J. C. Bendell, Luis T. Campos, et al.. (2010). Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13008–e13008. 6 indexed citations
9.
Camacho, Luis H., et al.. (2010). Chemokine expression in tumor-to-tumor metastasis. Oncology Letters. 1(3). 449–452. 5 indexed citations
10.
Campos, Luis T., John Nemunaitis, J. Stephenson, et al.. (2009). Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 27(15_suppl). e15505–e15505. 9 indexed citations
11.
Schreeder, Marshall T., Robert A. Figlin, Joseph J. Stephenson, et al.. (2008). Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. Journal of Clinical Oncology. 26(15_suppl). 16024–16024. 11 indexed citations
12.
Morrison, Vicki A., Mitchell D. Wong, Dawn L. Hershman, et al.. (2007). Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices. Journal of Managed Care Pharmacy. 13(4). 337–348. 97 indexed citations
13.
Campos, Luis T., J. Stephenson, F Swan, et al.. (2007). Daily dose of perifosine less toxic than weekly and active in patients with hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 25(18_suppl). 15072–15072. 3 indexed citations
14.
Justice, Glen R., J. Keßler, Luis T. Campos, et al.. (2005). A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Annals of Oncology. 16(7). 1192–1198. 12 indexed citations
15.
Campos, Luis T., et al.. (2005). Frequency of neutropenia-related events during chemotherapy and the use of pegfilgrastim and filgrastim in community practice: Results of the ACCEPT study. Journal of Clinical Oncology. 23(16_suppl). 8115–8115. 4 indexed citations
16.
West, William H., et al.. (2003). Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. The Oncologist. 8(1). 76–82. 11 indexed citations
17.
Weaver, CH, TJ Moss, B Zhen, et al.. (1998). High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplantation. 21(11). 1117–1124. 27 indexed citations
18.
Schwartzberg, Lee S., Robert Samuel Birch, William H. West, et al.. (1998). Sequential Treatment Including High-Dose Chemotherapy With Peripheral Blood Stem Cell Support in Patients With High-Risk Stage II-III Breast Cancer. American Journal of Clinical Oncology. 21(5). 523–531. 8 indexed citations
19.
Weaver, CH, Robert Birch, John D. Hainsworth, et al.. (1997). Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.. PubMed. 3(2). 83–90. 17 indexed citations
20.
Pazdur, Richard, Jaffer A. Ajani, Yehuda Z. Patt, et al.. (1990). Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.. Journal of Clinical Oncology. 8(12). 2027–2031. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maki Tanioka Breakdown of academic impact, for papers by Merry Tetef Breakdown of academic impact, for papers by Giovanni Codacci-Pisanelli Breakdown of academic impact, for papers by Masafumi Takimoto Breakdown of academic impact, for papers by Carla Kurkjian Breakdown of academic impact, for papers by Julian Adlard Breakdown of academic impact, for papers by Erwan Pencreach Breakdown of academic impact, for papers by William Dahut Breakdown of academic impact, for papers by M Chazal Breakdown of academic impact, for papers by Lei Deng
Rankless by CCL
2026